AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...

With plummeting apprehensions at the border, Trump's mass deportation campaign has played out in the public eye on city streets.